A detailed history of Stablepoint Partners, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Stablepoint Partners, LLC holds 27,848 shares of GILD stock, worth $2.58 Million. This represents 0.43% of its overall portfolio holdings.

Number of Shares
27,848
Previous 27,367 1.76%
Holding current value
$2.58 Million
Previous $2.13 Billion 9.76%
% of portfolio
0.43%
Previous 0.41%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$66.59 - $83.99 $32,029 - $40,399
481 Added 1.76%
27,848 $2.33 Billion
Q2 2024

Aug 02, 2024

BUY
$63.15 - $72.88 $202,143 - $233,288
3,201 Added 13.25%
27,367 $2.13 Billion
Q1 2024

Apr 23, 2024

BUY
$71.58 - $87.29 $410,153 - $500,171
5,730 Added 31.08%
24,166 $1.77 Billion
Q4 2023

Feb 12, 2024

BUY
$73.27 - $83.09 $1.35 Million - $1.53 Million
18,436 New
18,436 $1.49 Billion

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Stablepoint Partners, LLC Portfolio

Follow Stablepoint Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stablepoint Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stablepoint Partners, LLC with notifications on news.